Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-419-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.52 million
Profitability
Miscellaneous
Employees38
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.03. The firm had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.39 million. Syndax Pharmaceuticals had a negative return on equity of 108.44% and a negative net margin of 4,310.68%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
8 analysts have issued twelve-month price objectives for Syndax Pharmaceuticals' stock. Their predictions range from $5.00 to $26.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $15.6667 in the next twelve months. This suggests a possible upside of 53.1% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
What are Wall Street analysts saying about Syndax Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
- 1. Nomura analysts commented, "Trial Design, Details, Market Opportunity, and Biology p.4-6. The Ph1/2 trial outline for SNDX-5613 (the clinical program is now called AUGMENT) was disclosed on the earnings call presentation; the IND was cleared on July 10 (note here). The Ph1 portion will not select pt for mutations (per FDA request), but will begin with BID doses at an estimated efficacious dose (based on preclinical data). Possible issues may arise with PK due to the need for continuous drug exposure; expected tox based on preclinical experiments has not been published but will be announced at an upcoming medical meeting (ASH?). Ph2 expansion will use a yet-to-be disclosed biomarker to assess PD. SNDX-6352 in cGVHD RP2D Data Delayed (Now 2H20E vs. 3Q19E); Pts Available." (8/11/2019)
- 2. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (5/10/2019)
Has Syndax Pharmaceuticals been receiving favorable news coverage?
Headlines about SNDX stock have been trending negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Syndax Pharmaceuticals.
Are investors shorting Syndax Pharmaceuticals?
Syndax Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 646,800 shares, a decline of 7.7% from the June 30th total of 700,600 shares. Based on an average trading volume of 140,100 shares, the short-interest ratio is currently 4.6 days. Approximately 3.3% of the company's shares are sold short. View Syndax Pharmaceuticals' Current Options Chain.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Odonate Therapeutics (ODT), ArQule (ARQL), Radius Health (RDUS), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Stoke Therapeutics (STOK), Zymeworks (ZYME), Omeros (OMER), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ANI Pharmaceuticals (ANIP) and Axsome Therapeutics (AXSM).
What other stocks do shareholders of Syndax Pharmaceuticals own?
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)
- Mr. Michael A. Metzger, Pres & COO (Age 48)
- Mr. Richard P. Shea, CFO & Treasurer (Age 67)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.21%), Vanguard Group Inc. (3.80%), Renaissance Technologies LLC (1.59%), Sofinnova Investments Inc. (0.90%), Panagora Asset Management Inc. (0.73%) and Northern Trust Corp (0.69%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which major investors are selling Syndax Pharmaceuticals stock?
Which major investors are buying Syndax Pharmaceuticals stock?
SNDX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Panagora Asset Management Inc., Campbell & CO Investment Adviser LLC, Sofinnova Investments Inc., Prudential Financial Inc. and Acadian Asset Management LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $10.23.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $277.64 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.
What is Syndax Pharmaceuticals' official website?
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
